Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic planNo impact on cash runway or financing strategy as no milestone associated with these programs was expected within this three-year timeframeFocused investment on high‑value late‑stage assets Lusvertikimab and Tedopi® Multiple clinical catalysts expected from 2026 to 2028 Nantes, France, March 2, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: ...

Fox Corporation President and Chief Operating Officer John Nallen to Participate in Upcoming Deutsche Bank's 34th Annual Media, Internet & Telecom Conference [Accessibility Statement](https://www.cision.com/about/accessibility/) Skip NavigationNEW YORK and LOS ANGELES, March 2, 2026 /PRNewswire/ -- Fox Corporation (Nasdaq: FOXA, FOX) today announced that President and Chief Operating Officer John Nallen will participate in Deutsche Bank's 34th Annual Media, Internet & Telecom Conference on Monday, March 9, ...

Kroger Customers Can Enjoy Premium Convenient Meals in Minutes with Private Selection® Expansion [Accessibility Statement] (https://www.cision.com/about/accessibility/) Skip NavigationThe retailer makes mealtime deliciously convenient with affordable and globally inspired dishes.CINCINNATI, March 2, 2026 /PRNewswire/ -- Today, The Kroger Co. (NYSE: KR) is announcing an expansion of its Private Selection® brand with a new lineup of deliciously crafted premium and convenient meals thoughtfully developed and d ...

Core Insights - ADP has launched a new section within ADP Marketplace, introducing AI agents aimed at enhancing HR workflows and supporting organizations throughout the employee lifecycle [1] Group 1: AI Agents and Their Functionality - The new AI agents are designed to streamline operations by orchestrating workflows, allowing HR teams and managers to focus on higher-value tasks [1] - These agents can provide insights, ensure compliance with employment laws, and assist in talent acquisition by identifying qualified candidates and maintaining engagement [1] Group 2: Partnerships and Compliance - Partners offering AI solutions in the ADP Marketplace must adhere to ADP's AI principles, which emphasize human oversight, monitoring, explainability, and bias mitigation [1] - The curated set of AI agents includes partners such as Absorb, Aquera, G-P, Built, Employ, Praisidio, Salary.com, Tapcheck, MakeShift, Payactiv, and Quantum Workplace [1] Group 3: Commitment to Responsible AI - All AI-enabled partner solutions featured on ADP Marketplace are committed to responsible AI principles, focusing on privacy, bias mitigation, explainability, and ongoing monitoring [1] - ADP aims to make cutting-edge AI accessible and integrated into everyday work, reflecting its commitment to innovation and human-centered solutions [1]

Core Insights - Wave Life Sciences Ltd. is a clinical-stage genetic medicine company focused on developing stereopure oligonucleotides targeting RNA for therapeutic applications [1] - The consensus price target for WVE has increased from $29.79 last year to $32, indicating growing optimism among analysts [2] - The company is developing treatments for conditions such as amyotrophic lateral sclerosis, Huntington's disease, and Duchenne muscular dystrophy, with collaborations with Pfizer and Takeda enhancing its capabilities [3] - Despite reporting a quarterly loss of $0.30 per share, the company exceeded revenue estimates, providing some reassurance to investors [4] - Analyst Tiago Fauth from Wells Fargo has set a more cautious price target of $11 for WVE, reflecting a conservative outlook on the stock's future performance [5] Price Target Trends - The average consensus price target for WVE has shown a positive trend, increasing from $29.79 to $32 over the past year [2][6] - This upward trend suggests analysts are optimistic about the company's future prospects, likely due to advancements in clinical programs and collaborations [2][6] Company Developments - Wave Life Sciences is actively pursuing treatments for serious conditions and has established partnerships with major pharmaceutical companies, which may enhance its research capabilities and market reach [3][6] - The company's collaborations with Pfizer and Takeda are expected to contribute positively to its growth and investor sentiment [3] Financial Performance - In its Q4 2025 earnings call, Wave Life Sciences reported a loss of $0.30 per share, which was slightly below the Zacks Consensus Estimate of a $0.28 loss [4] - The reported loss marks a decline from the previous year's earnings of $0.17 per share, but the company managed to exceed revenue estimates, which may reassure investors [4][6]

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of directors of Hims & Hers Health, Inc. ("Hims†or the "Company†) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. IF YOU ARE A HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER, CLICK HERE TO PARTICIPATE. What Happened? On February 7, 2026, The New York Times re. ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Corcept Therapeutics Incorporated ("Corcept†or the "Company†) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CORCEPT THERAPEUTICS INCORPORATED (CORT), CONTACT THE LAW OFFICES OF HOWAR. ...

Paris, 2 March 2026, 06:00pm Issuer Name: Rubis (LEI: 969500MGFIKUGLTC9742)Category of securities: Ordinary shares (ISIN: FR0013269123)Period: From 23 to 27 February 2026 Upon the authorisation granted by the Ordinary Shareholders’ Meeting held on 12 June 2025 to implement a share buyback programme, the Company carried out, between 23 and 27 February 2026, the repurchases of its own shares in view to transfer them to employees and/or corporate officers of the Company and/or companies related to it in the c ...

Group 1 - Ilkka Oyj acquired 3,000 shares at an average price of EUR 4.29 per share, totaling EUR 12,870 on 2 March 2026 [1] - After the acquisition, Ilkka Oyj holds a total of 100,034 treasury shares [1] Group 2 - Ilkka is a marketing and technology company that provides professional, data, and technology services in digital marketing and communications [2] - The core of Ilkka's business includes several key entities such as the software company Liana, the Swedish subsidiary Ungapped, and the data-driven sales and marketing expert Profinder [2] - Ilkka's international focus is particularly on Sweden and emerging markets in the Middle East, supported by a team of approximately 330 experts in marketing, technology, and data [2]

Press release2 March 2026 Information on the availability of the 2025 Universal Registration Document Paris, 2 March 2026 – Clariane (CLARI - ISIN: FR0010386334) announces the release of its 2025 Universal Registration Document. The 2025 Universal Registration Document was filed with the French Financial Markets Authority on 27 February 2026 in ESEF format, under number D.26-0054. This 2025 Universal Registration Document, established for the financial year ended on 31 December 2025, includes in particular ...